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Key Points
• Real-world data on
caplacizumab confirm
treatment efficiency in
60 patients with aTTP
independent of timing
and treatment
modalities.
•Use of caplacizumab
resulted in a reduced
need for PEX support-
ing frontline use of
caplacizumab for all
patients.
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition.
In 2018, the nanobody caplacizumabwas approved for the treatment of adults experiencing an
acute episode of aTTP, in conjunctionwith plasma exchange (PEX) and immunosuppression for
a minimum of 30 days after stopping daily PEX. We performed a retrospective, observational
analysis on the use of caplacizumab in 60 patients from 29medical centers in Germany during
acute disease management. Caplacizumab led to a rapid normalization of the platelet count
(median, 3 days; mean 3.78 days). One patient died after late treatment initiation due to aTTP-
associated complications. In 2 patients with initial disease presentation and in 4 additional
patients with laboratory signs of an exacerbation or relapse after the initial therapy, PEX-free
treatment regimens could be established with overall favorable outcome. Caplacizumab is
efficacious in the treatment of aTTP independent of timing and ancillary treatment modalities.
Based on this real-world experience and published literature, we propose to administer
caplacizumab immediately to all patients with an acute episode of aTTP. Treatment decisions
regarding the use of PEX should be based on the severity of the clinical presentation and known
risk factors. PEX might be dispensable in some patients.
Submitted 2 April 2020; accepted 8 May 2020; published online 7 July 2020. DOI
10.1182/bloodadvances.2020001973.
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Introduction
Acquired thrombotic thrombocytopenic purpura (aTTP) is caused
by the formation of inhibitory and, less frequently, noninhibitory
autoantibodies directed against a disintegrin and metalloprotease
with thrombospondin type 1 motifs, member 13 (ADAMTS13). von
Willebrand factor (VWF)–multimers form on endothelial cells where
they activate and bind platelets upon endothelial injury and protect
procoagulatory factor VIII from proteolytic degradation. In Germany,
the incidence of aTTP is reported with 2.1 to 2.2 cases per 1 million
adults per year.1,2 Acquired TTP presents as acute onset micro-
angiopathic hemolytic anemia with profound thrombocytopenia.
Additional complaints depend on the predominantly affected organ
systems but may be absent. aTTP is a medical emergency requiring
urgent plasma exchange (PEX) and immunosuppressive agents. If
untreated, mortality may reach up to 90%.
Recently, the therapeutic options have been expanded by the
approval of a novel anti-VWF humanized single-variable domain
nanobody, caplacizumab, inhibiting VWF-platelet aggregation. In
2 double-blind controlled trials, TITAN and HERCULES, caplacizu-
mab was compared against placebo in addition to PEX in 75 and
145 patients with aTTP.3,4 The TITAN trial reported an increased
number of relapses in the intervention group after termination of
caplacizumab after 30 days, which was attributed to unresolved
autoimmune activity. Therefore, the HERCULES protocol included
the option to extend caplacizumab treatment beyond 30 days
after PEX in case of sustained autoimmune activity. The treatment
extension was able to decrease relapse rates significantly.
Administration of caplacizumab resulted in a reduced time to
platelet count response in an analysis stratified by neurological
involvement. It also reduced the recurrence rate compared with
placebo (12% vs 38%; P , .001). A composite outcome event of
thrombotic thrombocytopenic purpura (TTP)–related death, re-
currence of TTP, or a thromboembolic event during the treatment
period was 74% lower with caplacizumab than with placebo (12%
vs 49%; P , .001). Consequently, the drug was rapidly approved
and can be prescribed in Germany since October 2018.
Real-world evidence may help to generalize findings from well-
controlled clinical trials with low risk of bias and confirm the
effectiveness of novel treatment approaches under ordinary
circumstances. Whether caplacizumab should be used as frontline
therapy or only in cases of severe organ dysfunction, refractory
disease, exacerbation, or relapse remains elusive. To provide
a rationale for the treatment with a potentially lifesaving but also
expensive drug, we analyzed a cohort of 60 patients with aTTP that
received caplacizumab between June 2018 and December 2019.
Methods
Study design and participants
This study was conducted as a retrospective, observational study at
29 German medical centers. In total, 60 patients (;90% of all
patients treated in Germany) with aTTP were identified who
received caplacizumab between June 2018 and December 2019.
The PLASMIC (platelets, lysis, active cancer, stem cell or solid
organ transplant, MCV, INR, and creatinine) score (developed as
a clinical predictive tool of severe ADAMTS13 deficiency) was
determined retrospectively as published previously.5,6 Day 0 was
defined as the day of diagnosis as indicated by the treating
physician, beginning of aTTP-specific therapy, or a reported
ADAMTS13 activity measurement of less than 10%. It is important
to note that the reported date of ADAMTS13 activity measurements
may not reflect the time point when the results became available to
the treating physician. Testing was not available on site at most
centers and results may have been reported with a delay of several
days. Retrospectively, aTTP had likely begun prior to the day of
diagnosis in some patients but was not recognized or treated under
the presumption of a different diagnosis.
Time to normalization of platelet count after the start of caplacizumab
treatment was defined as the first day with a count $150 3 109/L.
Clinical remission, exacerbation, refractory disease, and relapse were
defined as published previously with the exception that reinitiation of
PEX was not a prerequisite of exacerbation and relapse because
some of these instances were managed with conservative treatment
only.7 Treatment according to the HERCULES protocol was defined
as caplacizumab started before or after the first PEX and continued for
a minimum of 30 days and a maximum of 58 days after the last PEX
treatment. Frontline use was defined as a treatment started within
72 hours after diagnosis. Presence of acute kidney injury according
to Kidney Disease: Improving Global Outcome (KDIGO) was
determined by comparing the highest with the lowest serum creatinine
measurement during the follow-up. Lowest serum creatinine was
assumed to be the baseline. Urinary output was not taken into
consideration because this information was not available.
Statistical analysis
Given the exploratory nature of this study, no sample size
calculation and no adjustments for multiple testing were performed.
All results are given as median (range) or mean with 95%
confidence interval (CI) when appropriate, except for Figure 1, where
the standard errors of the means are reported. Statistical analysis
was conducted using Prism version 8.0.1 (GraphPad Software, San
Diego, CA). Figures and tables were designed and composed using
Microsoft Office (Microsoft, Seattle, WA) and Adobe Illustrator
(Adobe Systems Software Ireland Ltd, Dublin, Ireland).
Results
Individual patient characteristics, treatment modalities as well as
individual courses comprising platelet counts, ADAMTS13 activity
measurements, and relevant adverse events are shown in supple-
mental Figures 1 and 2.
Patient characteristics and initial disease
presentation
Patient characteristics and initial disease presentation are shown in
Figure 1 and Table 1. Sixty patients were followed up for a median
of 108.5 days (range, 5-330 days) for a total of 7484 patient days.
Female patients comprised 70.0% of the patient population (42 of
60 patients). Average age at onset was 45.7 years (range, 22-83
years). Fifty-nine patients were of white descent and one of African
descent. Median body mass index (BMI) was 26.8 kg/m2 (range,
16.0-42.6 kg/m2). In 76.7% of the cases (46 of 60 patients), aTTP
was considered a primary manifestation when presented with
a disease relapse (23.3%; 14 of 60 patients). An initial ADAMTS13
activity of ,10% was reported in all patients (median ,0.3%;
range, 0% to 8.0%). The median initial thrombocyte count was
13 3 109/L (range, 3-82 3 109/L). Eight patients (13.3%)
3086 VO¨LKER et al 14 JULY 2020 x VOLUME 4, NUMBER 13
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/4/13/3085/1748086/advancesadv2020001973.pdf by M
AX-D
ELBR
U
EC
K-C
EN
TR
U
M
 FU
ER
 M
O
LEK M
ED
IZIN
 user on 10 July 2020
presented with significant neurological symptoms as judged by
a Glasgow coma scale (GCS) score of,13. All patients presented
with a PLASMIC score of $4, indicating intermediate to high risk
for thrombotic microangiopathy (TMA) related to ADAMTS13 de-
ficiency. Thirty-six patients had a PLASMIC score of 7 (60.0%); 22
patients had a score of 5 or 6 (36.7%), and 1 patient had a score of 4
(1.7%). In only 32 subjects (53%), troponin was measured at least
once. Twenty-seven of 32 patients (84%) with troponin measurements
showed levels above the upper limit of normal suggesting concomitant
myocardial damage. Three patients (5.0%) presented with a serum
creatinine above 2.0 mg/dL (152.6 mmol/L). During the disease
course, 44 (73%) patients sustained acute kidney injury KDIGO stage
1 to 3 of any cause: 31 patients reached KDIGO stage 1; 7 patients
reached KDIGO stage 2; and 6 patients reached KDIGO stage 3.
Disease course and treatment modalities
Disease course and treatment modalities are listed in Tables 2 and
3. Due to the severity of symptoms and the need for PEX, most
patients (44 of 60 patients; 73.3%; 6 patients had data missing)
were initially treated on intensive care units (ICU), accumulating
301 ICU days with a median of 4 days per patient. Patients were
discharged from the hospital after 18 days (range, 5 to 79 days).
Patients received a total of 1979 daily doses of caplacizumab with
a median of 34.0 doses per patient (range, 2 to 89 doses). Only 8
(13.3%) patients were treated according to the HERCULES trial
protocol. Caplacizumab treatment was started with a median of
3 days after diagnosis (range, 0 to 27 days). Caplacizumab was
used as a frontline agent in 35 of 60 patients (58.3%); 25 of 60
patients (41.7%) received the drug to treat disease exacerbation or
refractoriness or to prevent relapse. In an analysis of platelet counts
and lactate dehydrogenase immediately before and after the start of
the caplacizumab treatment, we could detect a robust tendency
toward improvement as an indicator of waning TMA (Figure 2). Platelet
counts normalized to above 1503 109/L in a median of 3 days (range,
1 to 13 days) after commencing caplacizumab treatment (Figure 3).
Fifty-eight patients (96.7%) received PEX, with a median of 9 PEX
treatments (range, 2 to 41 treatments). In the majority of cases, PEX
(38 of 60 patients; 63.3%) was continued until platelets normalized
for at least 1 day. In 15 instances, PEX was stopped immediately
when platelet count rose above 150 3 109/L. In 10 instances, PEX
was stopped with stabilizing or rising platelets, albeit still below the
lower limit of normal. Four patients were taken off PEX while on
caplacizumab treatment with platelets still below 100 3 109/L. In
one of these patients, PEX was already stopped after only 2 PEX
procedures and 1 dose of caplacizumab when the platelet count had
risen from 9 3 109/L to 42 3 109/L (patient 36). Fifty-nine patients
(98.3%) received glucocorticoids with a median dose of 1.40 mg
(range, 0.64 to 15.11 mg) per kg of body weight as the initial dose.
One patient did not receive glucocorticoids for safety concerns due to
an acute HIV infection. A total of 76.6% of patients (46 of 60 patients)
received high-dose glucocorticoids, defined as a dose of .1.0 mg/kg
of body weight. In 8 patients, the respective data were missing. Ten
patients received additional immunosuppressants to treat aTTP.
Azathioprine was used in 3 cases; mycophenolate was used in 3
cases, ciclosporin was used in 2 cases, and hydroxychloroquine and
vincristine were used in 1 patient each. Forty-eight patients (80.0%)
were treated with 1 to 6 doses of rituximab with a median cumulative
dose of 2000 mg (range, 562.5 to 5000 mg). On average, patients
received the first dose of rituximab on day 7 (range, day 0 to day 26).
In 11 patients (18.3%), rituximab was used as a frontline agent.
The clinical courses and outcomes are summarized in Table 3.
Clinical remission was achieved in 56 patients as defined in Scully
et al.7 For 3 patients, insufficient follow-up was available (patients
10, 19, and 59) to assess clinical remission. One patient (patient
18) died of aTTP complications. This patient with known aTTP
developed symptoms 2 weeks before admission. PEX treatment
was commenced immediately after admission into the hospital but
did not improve aTTP activity (supplemental Figure 1). On day 3, the
patient developed abdominal symptoms and received the first dose
of caplacizumab 4 hours prior to intestinal surgery. This resulted in
an immediate thrombocyte response. Surgery revealed the
presence of mesenteric ischemia and intestinal gangrene, and
a resection was performed. Thrombotic occlusion of the vessels
was detected in the pathological examination. Despite surgery and
treatment with caplacizumab, the patient died the following day as
a result of sepsis and multiorgan failure. One patient (patient 49)
was ruled to have achieved clinical remission despite persistent
thrombocytopenia as the platelet count stabilized at the previously
established level related to concomitant liver cirrhosis. In 19
patients (31.7%), aTTP proved refractory to initial treatment without
caplacizumab. Thirteen of these 19 instances were classified as
severe, with platelets remaining below 30 3 109/L after 5 days of
PEX total (n)
PEX on caplacizumab (n)
First caplacizumab dose (d)
Total caplacizumab doses (n)
First rituximab dose (d)
Total hospital staya (d)
Total ICU staya (d)
0 20 40 60
Time [days]
80 100
Figure 1. Violin blots depict the distribution of main
treatment and outcome parameters. Red lines indicate
medians; blue lines indicate 75th and 25th interpercentile
quartile. aTotal stay includes before, during, and after caplaci-
zumab treatment.
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effective PEX. Twenty-three patients (38.3%) experienced any form
of exacerbation. Four patients sustained .1 episode of exacerbation
(1 patient with 3 episodes; 1 patient with 4 episodes). An exacerbation
occurred in 2 patients (3.3%; patients 19 and 30) while on daily
caplacizumab. Two patients were diagnosed with relapsing disease,
80 days and 43 days after the end of PEX respectively (3.3%; patients
33 and 54). All relapsing and refractory patients for whom such data
were available showed suppressed ADAMTS13 activity levels ,10%
at the time point of refractoriness or relapse.
Caplacizumab treatment without PEX
In this study, we report 2 cases in which the treating physicians
opted against standard of care and did not initiate PEX upon the
initial presentations (patients 37 and 56). This was based on shared
decision making with their patients. Patient 37 was admitted to an
external hospital because of facial paresthesia, aphasia, and
petechial bleeding. Magnetic resonance tomography ruled out
stroke. Laboratory results revealed TMA (platelets, 17 3 109/L;
hemoglobin, 7.5 g/dl; lactate dehydrogenase [LDH], 902 U/L;
schistocytes, 4.6%; haptoglobin, not detectable; and creatinine,
63.7 mmol/L). The patient was transferred to one of the participating
centers for treatment. The patient was informed about benefits and
risks of PEX and decided against the procedure. Five and 6 hours
after the first IV caplacizumab dose, the patient’s platelet count
increased to 303 109/L and 353 109/L, respectively (supplemental
Figure 1). The patient’s platelets normalized within 3 days. The
diagnosis of aTTP was confirmed by nondetectable ADAMTS13
activity and the presence of autoantibodies. Patient 56 had a history
of aTTP and presented with a mild relapse with nondetectable
ADAMTS13 activity, platelets of 62 3 109/L, and LDH of 298 U/L.
Table 1. Baseline patient characteristics and disease parameters of the cohort reported in this manuscript and the HERCULES trial
Germany*
(n 5 60) HERCULES cohort (N 5 145)4
Comparison of Germany vs HERCULES
(Fisher’s exact test), P
Age, mean (range), y 45.7 (22-83) 46 (18-79)
Female sex, % (n/total) 70 (42/60) 69 (100/145) ..9999
White, % (n/total) 98.3 (59/60) 71.0 (97/137) <.0001
BMI, median (range), kg/m2 (n 5 59) 27 (16.0-42.6) 30 (18-59)
First occurrence of TTP, % (n/total) 76.7 (46/60) 57 (82/145) .0072
Hemoglobin, initial, median (range), g/dL 8.2 (5.0-13.6) Placebo arm (n 5 63), 8.7 (6.4-15.1); verum arm
(n 5 62), 8.6 (5.9-15.9)†
Hemoglobin, minimum, median (range), g/dL 6.3 (4.5-10.9) Not reported
Platelets, initial, median (range), 3109/L 13.0 (3-85) 24 (3 – 133)
Platelets, minimum, median (range), 3109/L 10 (2-62) Not reported
LDH, initial, median (range), U/L 985 (316-2588) 422 (120-3343)
LDH, maximum, median (range), U/L 1088 (316-2918) Not reported
Troponin above ULN at any point, % (n/total) (n 5 32) 84.4 (27/32) cTnI above ULN at baseline, 49.0 (71/145)‡
Creatinine, initial, median (range), mmol/L 96.5 (52.2-470) 80 (35-717)
Creatinine, maximum, median (range), mmol/L 120.4 (55.8-470) Not reported
ADAMTS13 activity below 10%, % (n/total) 100 (60/60) 85 (123/145) .0004
ADAMTS13 antibody above 12 IU/ml (ULN) at any point,
% (n/total)
91.7 (55/60) Not reported
ADAMTS13 antibody concentration, maximum, median
(range), IU/ml
75.5 (0.0-131.6) Not reported
Glasgow Coma Scale, % (n/total) .1909
,13 13.3 (8/60) 8 (11/145)
13-15 83.3 (50/60) 91 (132/145)
Data missing 3.3 (2/60) 1 (2/145)
PLASMIC score, % (n/total)5-7
0-4 1.7 (1/60) Not reported
5-6 36.7 (22/60) Not reported
7 60.0 (36/60) Not reported
Data missing 1.7 (1/60) Not reported
Bold P values indicate statistical significance (P , .05).
cTnl, cardiac troponin; IULN, upper limit of normal.
*n 5 60 unless indicated otherwise due to missing data. Differences in the HERCULES cohort were tested using the Fisher’s exact test if sufficient data were available.
†Source data from Sanofi are on file shared by the company.
‡Data source is the Orphan Maintenance Assessment Report (EMA/541816/2018). Please note the difference in the time point of troponin assessment (at any time point in the German
cohort and at baseline in HERCULES).
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The patient received high-dose glucocorticoids and caplacizumab
without PEX. The patient’s platelets normalized within 4 days.
In addition, we detected 3 instances of exacerbation or relapse after
the initial caplacizumab treatment was stopped (patients 33, 42,
and 43) and 1 instance of exacerbation or relapse by inadvertent
omission of doses (patient 29), which could be successfully managed
by reinitiating the caplacizumab treatment without additional PEX. In
all cases, ADAMTS13 activities were still ,10%. Recurrence of
disease activity after the last dose of caplacizumab was detected at
a median of 6 days (range, 4-14 days).
Safety events
Overall, safety events were reported only sporadically. One major
bleeding complication in the form of recurrent vaginal hemorrhages
Table 2. Treatment modalities
Germany (n 5 60) HERCULES cohort (N 5 145)
Comparison of Germany vs HERCULES
(Fisher’s exact test), P
Rituximab treatment, % (n/total) 80 (48/60) 43 (63/145) ,.0001
Rituximab, % (n/total)
Frontline (within 72 h) 18.3 (11/60) 17 (25/145) .8398
Delayed 60.0 (36/60)
Data missing 1.7 (1/60)
Day of first rituximab after disease onset, median (range), d 7 (0-35) Not reported
Cumulative rituximab dose, median (range), mg 2000 (562.5-5000) Not reported
PEX treatment, % (n/total) 96.7 (58/60) 100 (145/145) .0846
Days of PEX treatment (n 5 58)
Median, no. (range) 9 (2-41)
Mean, no. (95% CI) 11.8 (9.5-14.2)
Days of PEX under caplacizumab treatment
Median, no. (range) 4 (0-22) Verum arm (n 5 72), 5 (1-35)
Mean, no. (95% CI) 5.3 (4.2-6.4) Verum arm (n 5 72), 5.8 (4.8-6.8)
Caplacizumab doses, median (range), no. 34.0 (2-89)
Caplacizumab treatment duration, median (range), d 34 (2-211) 35 (1-65)*
Caplacizumab as frontline (within 72 h), % (n/total) 58.3 (35/60) Not applicable
Caplacizumab start after disease onset, median (range), d 3 (0-27; 27) Not applicable
Treatment according to HERCULES protocol, % (n/total)† 13.3 (8/60) Not applicable
Steroid treatment, % (n/total)
Any dose 98.3 (59/60) 97 (140/145) .6734
High dose‡ 76.6 (46/60)
Non-high dose 8.3 (5/60)
Data missing 13.3 (8/60)
Steroid initial dose (n 5 51), median (range), mg/kg BW§ 1.40 (0.64-15.11) Not reported
Other treatments, % (n/total)
Mycophenolate 5.9 (3/60) 4 (6/145)
Hydroxychloroquine 1.7 (1/60) 2 (3/145)
Vincristine 1.7 (1/60) Not reported
Ciclosporin 3.3 (2/60) 1 (2/145)
Azathioprine 5.0 (3/60) Not reported
Splenectomy 0.0 (0/60) 2 (3/145)
IVIG 0.0 (0/60) 3 (4/145)
Bortezomib 0.0 (0/60) 1 (2/145)
Immunoadsorption 0.0 (0/60) 0.7 (1/145)
N 5 60 unless indicated otherwise.
BW, body weight; IVIG, IV immunoglobulin.
*Data source is the Orphan Maintenance Assessment Report (EMA/541816/2018). Differences from the HERCULES cohort were tested using the Fisher’s exact test if sufficient data
were available.
†Defined as caplacizumab start before or after first PEX and caplacizumab continued for a minimum of 30 d after last PEX treatment.
‡High doses are defined as $1 mg/kg body weight of prednisone equivalent.
§Milligram of prednisone or prednisone equivalence dose if another glucocorticoid has been used.
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2 weeks after delivery was reported in 1 patient (patient 8); as
a result, caplacizumab was initially paused and then stopped. Other
minor bleeding complications comprised epistaxis and gingival
bleeding without the need to stop caplacizumab. No patient
suffered debilitating hemorrhage. In all cases, with the exception
of patient 8 the need for red blood cell transfusions was deemed
related to ongoing hemolysis rather than active bleeding. Six
patients reported drug-related injection site reactions.
Discussion
Here, we summarize the clinical courses of the first patients treated
with caplacizumab in Germany during June 2018 and December
2019. Overall, our experience confirms the positive results of the
TITAN and HERCULES trials.3,4 Caplacizumab was effective in the
treatment of aTTP and led to a rapid normalization of the platelet
count (median, 3 days; mean, 3.78 days) in our cohort vs 2.69 and
3.0 days reported in HERCULES and TITAN.3,4 In HERCULES,
these calculations were stratified by neurological involvement.
Therefore, a direct comparison of values should not be considered.
The cohort reported herein shares many characteristics with the
HERCULES cohort but differs significantly in several important
aspects. In the German cohort, patients were predominantly of
white descent and presented more often as first manifestation of
aTTP rather than relapsing disease. All German patients were
reported with an ADAMTS13 activity below 10% (median, ,0.3%;
range, ,0.3% to 8.0%), whereas the HERCULES cohort included
7 patients with other forms of TMA because ADAMTS13 activity
measurements were not part of the inclusion criteria. There appears
to be a trend toward leaner (BMI, 26.8 kg/m2 vs 30 kg/m2) but more
severely affected patients (median initial LDH, 985 IU/mL vs 422 IU/mL,
and median initial platelet count, 133 109/L vs 243 109/L), raising the
possibility that sicker patients may have been chosen for caplacizumab
treatment. Markers of organ damage including myocardial markers,
creatinine, and GCS score; however, did not differ widely. With
regards to treatment modalities, more German patients than those
in HERCULES received rituximab treatment at any time point with
no significant differences in steroid-regimens in the acute setting
and adjunct medications.
German patients accumulated almost twice as many days of PEX
(mean, 11.8 vs 5.8 days), remained longer on ICU (mean, 5.8 vs 3.4
days), and were hospitalized for a mean of 21.6 days, whereas in the
verum arm HERCULES patients averaged only 9.9 days of
hospitalization.4 This most likely reflects that German physicians
frequently used caplacizumab to treat refractoriness or exacerba-
tion rather than using it as a frontline agent. Caplacizumab was used
as a frontline agent in only 35 patients (58.3%). After the start of
caplacizumab, platelets normalized within a median of 3 days
(mean, 3.78), and only a median of 4 additional PEX were
necessary. Of note, the decision on PEX modalities and cessation
after thrombocyte recovery was highly variable and did not follow
a stringent protocol as in the HERCULES trial. Contrary to the
results in the 2 registrations trials without mortality during the study
period, 1 patient in this cohort died after a delayed caplacizumab
treatment initiation due to aTTP related complications.3,4
Taken together, these real-world data confirm the results from the
phase II and III studies and generate evidence of the effectiveness
of caplacizumab in the standard clinical care setting. They not only
demonstrate a clear trend toward an earlier control of the disease
with a reduced need for adjunct treatment but also argue in favor of
a frontline use of caplacizumab for all patients. It remains impossible
to predict individual treatment responses, clinical outcomes, and
PEX-associated complications or to identify those patients who
would have had a benign course without caplacizumab treatment. In
the real-world setting reported in this study, where, in most cases,
several PEX have already been applied at the time of starting
caplacizumab, there is no need for a first IV dose prior to PEX.
Instead, we recommend starting with a subcutaneous injection of
caplacizumab after PEX. In case of any delay in administrating PEX,
in patients with a known history of aTTP and/or high clinical
suspicion of relapse, the IV route remains an important option.
Table 3. Outcome data
Germany (n 5 60)
Mortality, % (n/total) 1.7 (1/60)
Follow-up, median (range), d 108.5 (5-330)
Clinical response, % (n/total)*
Achieved 93.3 (56/60)
Not achieved 3.3 (2/60)
Insufficient follow-up 3.3 (2/60)
Exacerbation, % (n/total) 38.3 (23/60)
While on caplacizumab 3.3 (2/60)
Refractory disease, % (n/total) 31.7 (19/60)
Refractoriness, grade, % (n/total)†
Severe 68.4 (13/19)
Mild 31.6 (6/19)
Relapse, % (n/total)
Relapsing disease 3.3 (2/60)
Insufficient follow-up 13.3 (8/60)
Time to final platelet normalization after diagnosis, median
(range), d
12 (3-152)
Reached at end of follow-up, % (n/total) 95.0 (57/60)
Not reached at end of follow-up, % (n/total) 5.0 (3/60)
Time to final platelet normalization after caplacizumab
start (n 5 64)‡§, d
Median (range) 3.0 (1-13)
Mean (95% CI) 3.78 (3.19-4.38)
Duration of hospital stay (n 5 59), d
Median (range) 18 (5-79)
Mean (95% CI) 21.6 (18.0-25.2)
Duration of ICU stay (n 5 54), d
Median (range) 4 (0-46)
Mean (95% CI) 5.8 (3.8-7.7)
*Clinical response as defined in Scully et al7: a sustained normalization of platelet counts
.150 3 109/L and of LDH ,1.5 upper limit of normal after cessation of PEX.
†Refractoriness grade as defined in Scully et al7. Refractory TTP is defined as persistent
thrombocytopenia ,50 3 109/L and persistently raised LDH levels despite 5 PEX and
steroid treatments. It is defined as severe if thrombocytopenia remains ,30 3 109/L.
‡Platelets .150 3 109/L. In 3 patients, platelet count did not normalize due to ongoing
sepsis or concomitant liver cirrhosis. These cases were excluded from the calculation
(patients 10, 49, and 53). One patient (patient 18) was not computed because of aTTP-
related death.
§Instances (n 5 64) rather than patient numbers are reported here reflecting the fact
that, in some patients, caplacizumab treatment was stopped and restarted. Every time
caplacizumab was restarted, the time to platelet normalization was measured again.
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In the HERCULES trial, all patients were required to continue on
PEX for 2 days after the platelet count normalized.4 This may be
dispensable when caplacizumab is administered concomitantly.
Our data suggest that PEX can be stopped when platelets rise to
values above 100 3 109/L to 150 3 109/L, perhaps even earlier.
Two recent case reports have suggested that even treatment
without PEX is feasible in selected patients albeit off label.8,9 In the
German cohort, we report on 6 instances with acute aTTP disease
activity treated without PEX. As a consequence, the necessity and
duration of plasmapheresis to treat acute episodes of aTTP is
a matter of debate. In certain cases, PEX might be dispensable, in
particular, if the disease activity is detected early and clinical
symptoms are mild. However, it remains unclear whether the
reduction of PEX in aTTP is solely beneficial or may also have
detrimental effects with regard to maintaining long-term remission. It
may be hypothesized that reducing PEX reduces procedure-
associated complications and prevents further immunization with
ADAMTS13 antigens and an increase of the ADAMTS13 inhibitor
concentration that is frequently observed.10 In contrast, less PEX may
not be as effective in depleting tissue depots of ADAMTS13 antibodies
and reduces the amount of supplemented ADAMTS13 protein.
Our retrospective observational study has several limitations.
Patients were treated in 29 different centers with 1 to a maximum
of 8 patients. Based on the published aTTP disease incidence in
Germany of 2.1 cases per 1 million adults per year, we assume
;200 to 250 aTTP cases during the observation period.2 Hence,
the cohort reported herein comprises an estimated 25% to 30% of
cases treated for aTTP during this time period. One might speculate
whether there is a bias with respect to disease severity and the use
of caplacizumab. Moreover, we do not have detailed information
about the duration from disease onset and first clinical symptoms to
the time point when the diagnosis of aTTP was made, as well as
when and how often the patients contacted professional health
care providers during this period. The treatment regimens were
heterogenous and based on individual patient characteristics rather
than study protocols. A similar heterogeneity has been observed in
the TITAN and HERCULES trials as well as in a national survey and
reflects the fact that only a few randomized trials have been
performed in patients with aTTP.3,4,11
In conclusion, our data confirm the results reported in the TITAN
and HERCULES trials in the German population in a real-world
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setting despite considerably heterogenous treatment regimens.
This real-word evidence allows us to generalize the effectiveness of
caplacizumab to treat acute episodes of aTTP beyond the internal
validity of randomized controlled trials.12 Based on these data and
the available literature, we propose to administer caplacizumab to all
patients with an acute episode of aTTP and to administer PEX until
thrombocytes rise above 100 3 109/L to 150 3 109/L. In selected
patients, treatment without PEX seems to be an option. A
randomized study is required to clarify this important topic.
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